T. Rowe Price Investment Management Inc. Makes New Investment in BioNTech SE (NASDAQ:BNTX)

T. Rowe Price Investment Management Inc. acquired a new stake in shares of BioNTech SE (NASDAQ:BNTX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 53,336 shares of the company's stock, valued at approximately $6,078,000.

Other large investors also recently bought and sold shares of the company. Jones Financial Companies Lllp grew its holdings in BioNTech by 110.3% in the 4th quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock valued at $53,000 after buying an additional 246 shares in the last quarter. Quintet Private Bank Europe S.A. lifted its holdings in shares of BioNTech by 823.5% in the 4th quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company's stock worth $88,000 after acquiring an additional 700 shares during the last quarter. Allianz SE purchased a new position in shares of BioNTech during the 4th quarter worth approximately $90,000. GAMMA Investing LLC increased its holdings in BioNTech by 48.2% in the 4th quarter. GAMMA Investing LLC now owns 923 shares of the company's stock valued at $105,000 after purchasing an additional 300 shares during the last quarter. Finally, Generali Investments CEE investicni spolecnost a.s. acquired a new position in BioNTech during the fourth quarter worth $137,000. Hedge funds and other institutional investors own 15.52% of the company's stock.

BioNTech Stock Down 1.7 %

BNTX stock traded down $1.72 during midday trading on Thursday, hitting $102.43. 984,983 shares of the company's stock were exchanged, compared to its average volume of 910,259. The stock has a market capitalization of $24.58 billion, a price-to-earnings ratio of -48.78 and a beta of 1.07. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The firm has a 50 day moving average price of $100.82 and a 200-day moving average price of $110.34. BioNTech SE has a 12-month low of $76.53 and a 12-month high of $131.49.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings results on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.38 by $0.70. The business had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business's revenue was down 19.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.90 earnings per share. On average, analysts anticipate that BioNTech SE will post -3.88 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Morgan Stanley dropped their price objective on BioNTech from $145.00 to $139.00 and set an "overweight" rating for the company in a research note on Tuesday, March 11th. HC Wainwright dropped their target price on BioNTech from $150.00 to $145.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Truist Financial initiated coverage on shares of BioNTech in a research report on Friday, January 10th. They set a "buy" rating and a $172.00 price target on the stock. Citigroup began coverage on shares of BioNTech in a report on Thursday, March 13th. They issued a "buy" rating and a $145.00 price objective for the company. Finally, Canaccord Genuity Group reiterated a "buy" rating and issued a $171.44 target price on shares of BioNTech in a report on Tuesday, March 11th. Three equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $143.44.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.